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the granulomatous type of the bystander tumor in-
flammation, in this case.
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Treatment of pemphigus vulgaris with rituximab 
effective, but not harmless
C Manrique, M Ebnöther, P Itin, P Häusermann, S Mül-
ler
Department of Dermatology, University Hospital 
Basel, Switzerland
Background: Pemphigus vulgaris (PV) is a rare, po-
tentially life-threatening autoimmune disease with 
a chronic relapsing course. The typical manifesta-
tion is characterized by fragile blisters and erosions 
of skin and mucosa, mediated by IgG autoantibod-
ies targeting the transmembranous adhesion mol-
ecules desmoglein 1 and 3. The mainstay of therapy 
has been oral corticosteroids and second-line im-
munosuppressive or –modulating therapies. Ritux-
imab, a chimeric monoclonal anti-CD20 antibody, 
has been reported to be effective in PV. It’s use re-
sults in clinical remission and has a steroid sparing 
effect. However, as shown in one of our two cases, 
severe side effects, particularly infections, must be 
considered.
Observations: Case 1: A 50 year-old man presented 
with a 10y-history of PV with skin and painful muco-
sal lesions. The disease had a recalcitrant, relapsing 
course despite adequate treatment with systemic 
corticosteroids and azathioprine.  As a result of fe-
mur head necrosis and hepatotoxicity this therapy 
regime was abandoned.  The patient was then suc-
cessfully treated with rituximab 375mg/m2  weekly 
for 1 month.  A complete remission was observed 
and could be maintained so far.
Case 2: A 34 year-old man presented with blisters 
on the skin as well as mucosal ulcerations, persisting 
for 2 years. The Initial therapy with systemic cortico-
steroids and azathioprine lead to complete remis-
sion. After 12 months it came to a relapse of skin 
lesions. Finally, rituximab 375 mg/m2 weekly, over 
4 consecutive weeks, showed a successful clinical 
response. After the third infusion the patient devel-
oped an enterovirus meningitis. Due to this severe 
side effect rituximab was discontinued. 
Conclusions: PV continues to be a challenging bul-
lous dermatosis, although its mortality rate could be 
decreased by immunosuppressive treatment. There 
is increasing evidence of the efficacy of rituximab as 
a second- or third-line therapy in cases resistant to 
previous therapies. However potential severe side-
effects can occur and must be considered. 
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Periungual erythemas in HIV-seropositive patient 
M Ebnöther, P Itin , A Arnold 
Department of Dermatology, University Hospital 
Basel, Switzerland
Background: In HIV-infected patients mucocutane-
ous findings are frequent, so are viral, bacterial, fun-
gal and noninfectious etiologies. Some skin disor-
ders are nearly exclusively found in HIV-seropositive 
individuals, such as Kaposi’s sarcoma, oral hairy leu-
koplakia and bacillary angiomatosis, whereas oth-
ers are also observed in general population. 
Periungual erythemas in HIV-infected people have 
been described before, often associated with anti-
bodies against HCV.
Observations: A 50-year-old, homosexual man pre-
sented with periungual erythemas, with redness of 
fingers and toes restricted to the distal parts. The le-
sions were painless and persistent for many years. 
The patient’s personal history revealed, except for 
a fourthfold myocardial infarction at the age of 48 
years, no other disorders. Further blood investiga-
tions showed a seropositive HIV-test, negative HCV 
antibodies and negative antinuclear antibodies.
Conclusions: Dermatologic manifestations are very 
common in HIV-infected patients and may be the 
first clue of infection. The exact cause of periun-
gual erythemas is not known yet. It was speculated 
that the vascular reactions resulting in red fingers 
might be due to association of HIV infection and 
hepatitis viruses. In other studies erythemas of the 
proximal nailfold in HIV-positive patients have been 
described without underlying chronic disease other 
than HIV, like mentioned above.
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The interaction of plectin with intermediate fila-
ments is modulated by phosphorylation of its car-
boxyl extremity by MNK2 and PKA
B Favre1, J.-E. Bouameur1, Y. Schneider2, P. Lingasamy1, 
R. Hobbs3, L. Fontao2, K. Green3, L. Borradori1
1 Departments of Dermatology, Insel-University 
Hospital of Berne, Switzerland
2 Department of Dermatology, University Hospital 
of Geneva, Switzerland
3 Department of Pathology, Northwestern Univer-
sity Feinberg School of Medicine, Chicago, USA
Plectin is a versatile cytolinker, tethering the inter-
mediate filament (IF) network to specific plasma 
membrane sites and organelles, thereby contribut-
ing to the maintenance of the cytoarchitecture and 
cell resilience in tissues such as the skin and skeletal 
muscle. Nevertheless, plectin-IF connections must 
be transitory regulated during processes involving 
a remodeling of the cell shape. Here, we have identi-
fied serine 4642 in the carboxyl extremity of plectin 
as an in vivo phosphosite. In various cell lines plec-
tin phosphorylated at S4642 was less localized to IFs 
than the total pool of plectin. In cell wound heal-
ing assays, migrating cells had an increased level 
of plectin phosphorylated at S4642, whereas in the 
hemidesmosomes of the epidermis and cultured 
keratinocytes plectin was mainly unphosphorylated 
at S4642. Various binding assays revealed that phos-
phorylation of S4642 inhibits the binding of recom-
binant plectin proteins to various types of IFs. The 
phosphorylation level of plectin S4642 in HeLa cells 
was increased by various stimuli. By using specific 
protein kinase (PK) inhibitors we identified two dif-
ferent kinases responsible for phosphorylating plec-
tin S4642, the MAPK-interacting kinase 2 (MNK2), 
downstream ERK1/2, and cyclic AMP-dependent PK P
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(PKA). Our data provide novel insights into the func-
tion of the carboxyl tail of plectin, whose genetic 
truncation causes severe epidermolysis bullosa, my-
opathy and central nervous system manifestations 
in affected patients, by revealing its key role in the 
regulation of plectin linkage to IFs.
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Baseline serum tryptase show increasing levels 
with age
L Felderer, P Schmid-Grendelmeier
Institute of dermatology, University Hospital of Zu-
rich, Zurich
 
Background: An elevated basal serum tryptase con-
centration are regarded as risk factors for more se-
vere anaphylactic reactions especially to Hymenop-
tera venom. The aim of this retrospective study was 
to determine to what degree serum trpytase con-
centrations depends on age or gender.
Methods: Basal serum levels of 3648 non-mastocy-
totic patients investigated at our unit were retro-
spectively analysed. Patients had their blood exami-
nation done due to a systemic anaphylactic reaction 
but with at least a one month interval due to the 
allergic event. Serum values were determined by a 
commercially available ELISA kit (FluoroEnzymeIm-
munoAssay ImmunoCAP®, Phadia AB, Uppsala, 
Sweden). Patients with elevated serum tryptase lev-
els of ≥ 11.4 ug/l were analysed separately.
Results: Over all patients (mean age 42.3 years, 
range 5-79 year; 1980 females/58.51%), a mean val-
ue for serum tryptase of 6.38 ug/l was found. 3384 
out of 3648 patients (92.76%) showed normal trypt 
ase values < 11.4 ug/l (mean 4.24 ug/l.) For this sub-
group a significant increase of mean serum tryptase 
according to age was found (p < 0.001). Looking at 
sex- dependent differences values, a significant dif-
ference was measured as men reached higher mean 
tryptase values (4.48 ug/l) than women 4.07 ug/l (p 
< 0.001).
Conclusions: Age and gender should be consid-
ered when analysing serum tryptase levels; older 
and tend to have higher mean levels within normal 
ranges of basal serum tryptase. In our collective also 
males tend to have higher basal levels than female 
patients.
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Low baseline immunoglobulin titers to pneumo-
coccal antigens are associated with higher fre-
quency of infections
L Fischer1, E Laffitte2, S Lopes3,  P. Francis Gerstel4, C-A 
Siegrist5, J Seebach4, C Ribi6  
1 Department of dermatology, University Hospital 
of Lausanne, Lausanne
2 Department of dermatology, University Hospital 
of Geneva, Geneva
3 University of Geneva, Geneva
4 Department of immunology and allergology, Uni-
versity Hospital of Geneva, Geneva
5 Center for vaccinology and neonatal immu-
nology, University Hospital of Geneva, Geneva 
6 Department of immunology and allergology, Uni-
versity Hospital of Lausanne, Lausanne
Objectives: To assess the utility of pneumoccal poly-
saccharidic vaccine (PPV) in patients with inflamma-
tory skin disorders treated with immunosuppres-
sive drugs.
Methods: Observational study in outpatient setting. 
Inclusion criteria were: age ≥ 18 years, daily Predni-
sone equivalent of ≥ 20mg and/or immunosuppres-
sive treatment. Exclusion criteria were: previous vac-
cination with PPV, intravenous immunoglobulins 
and ongoing pregnancy. Serum immunoglobulin G 
(IgG) levels to six S.pneumoniae serotypes (14, 19, 
23F, 9N, 11A, 17F) and total immunoglobulin levels 
by nephelometry. Seropositivity was defined as IgG 
≥ 0,5 mg/l for ≥  4/6 pneumococcal serotypes. Pa-
tients below this threshold at baseline received PPV. 
Vaccine response and tolerance was assessed after 
one month using the physician’s global assessment 
(PGA) score and the 36-item short form health sur-
vey (SF-36) and in psoriatics by the Psoriasis Area 
and Severity Index (PASI). Serology was repeated a 
fter one year and patients questioned for intercur-
rent infection events needing medical attention. 
End points were the proportion of seropositive pa-
tients, response and tolerance to PPV and the rate of 
infections during follow-up.
Results: Sixty-one patients were included, with a 
mean age of 56 ±15 years. Forty-five (74%) had pso-
riasis and 16 (26%) other autoimmune skin diseases. 
All had immunosuppressants and 12 (20%) addi-
tional systemic corticosteroids. Immunosuppres-
sants were TNF-alpha blocking agents in 35 (57%), 
human interleukin-12/23 monoclonal antibody in 6 
(10%), methotrexate in 17 (23%), azathioprine in 11 
(18%) and chlorambucil in one. At baseline, 11 (18%) 
were seronegative. This was significantly associated 
with low total IgG levels (p=0.008) and infections 
in the preceding 3 months (p=0.045). Ten patients 
received PPV, with excellent tolerance. Eight (80%) 
reached seropositive thresholds after PPV, although 
with modest antibody titers. Infections of any kind 
occurred during follow-up in 12/47 (26%) patients 
seropositive at baseline and in 5/7 (71%) initially 
seronegative patients despite immunization (p= 
0.026). The rate of airway infections was not differ-
ent between study arms.
Conclusions: Low total IgG and a higher frequency 
of infections in immunosuppressed dermatological 
patients should prompt the evaluation/reactivation 
of pneumococcal immunity, now that more immu-
nogenic conjugate vaccines are available.
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Captopril-induced leucocytoclastic vasculitis
L Flatz, I Gschwind, M Vernez, D Hohl, M Gilliet, L Feld-
meyer
Department of Dermatology, Lausanne
Captopril is an angiotensin-converting enzyme 
(ACE) inhibitor widely prescribed for hypertension 
and heart failure. Common cutaneous side effects 
of captopril include angio-edema, anaphylactoid 
reactions, maculopapular eruptions and exfoliative P
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